Coverage
-
May 20, 2025
Novo Nordisk is urging a North Carolina federal court not to vacate its order permitting the Danish drugmaker to seek information bolstering its $800 million fraud claims stemming from a hypertension drug deal, saying the testimony is needed to preserve assets as it pursues arbitration of its claims.
1 other articles on this case.
View all »